| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Our intelligent routing software solves complex routing challenges with unrivaled precision to enhance safety, reduce costs and create efficiencies.
nToggle delivers heightened efficiency and transparency for buyers and sellers amidst the rapid rise of programmatic advertising. Its algorithm-driven software platform helps supply and demand partners manage the ever expanding bid stream. nToggle`s big data platform “toggles” real time bidding requests across all digital media utilizing the latest analytical and machine learning techniques to optimally match supply and demand.
Harnessing the power of tomorrow’s technology to accelerate National Security today.
Adaequare is a Chantilly, VA-based company in the Software and Internet sector.